Extractable surface proteins of indigenous probiotic strains confer anti-adhesion knack and protect against methicillin-resistant Staphylococcus aureus induced epithelial hyperpermeability in HT-29 cell line

Can proteins, protein hydrolysates and peptides cooperate with probiotics to inhibit pathogens?

Studies have shown that probiotics can effectively inhibit pathogens in the presence of proteins, protein hydrolysates and peptides (protein derivates). However, it is still unclear the modes of probiotics to inhibit pathogens regulated by protein derivates. Therefore, we summarized the possible effects of protein derivates from different sources on probiotics and pathogens. There is abundant evidence that proteins and peptides from different sources can significantly promote the proliferation of probiotics and increase their secretion of antibacterial substances. Such proteins and peptides can also stimulate the adhesion of probiotics to intestinal epithelial cells and contribute to regulating intestinal immunity, but they seem to have the negative effects on pathogens. Moreover, a direct effect of proteins on intestinal cells is summarized. Whether or not they can cooperate with probiotics to inhibit pathogens using above possible mechanisms were discussed. Furthermore, there seems to be no consistent conclusions that protein derivates have synergistic effects with probiotics, and there is still limited evidence on the inhibiting patterns. Therefore, the existing problems and shortcomings are noted, and future research direction is proposed.

Enhancing Human Superorganism Ecosystem Resilience by Holistically ‘Managing Our Microbes’

Microbes in the 21st century are understood as symbionts ‘completing’ the human ‘superorganism’ (Homo sapiens plus microbial partners-in-health). This paper addresses a significant paradox: despite the vast majority of our genes being microbial, the lack of routine safety testing for the microbiome has led to unintended collateral side effects from pharmaceuticals that can damage the microbiome and inhibit innate ‘colonization resistance’ against pathobionts. Examples are discussed in which a Microbiome First Medicine approach provides opportunities to ‘manage our microbes’ holistically, repair dysbiotic superorganisms, and restore health and resilience in the gut and throughout the body: namely, managing nosocomial infections for Clostridioides difficile and Staphylococcus aureus and managing the gut and neural systems (gut–brain axis) in autism spectrum disorder. We then introduce a risk analysis tool: the evidence map. This ‘mapping’ tool was recently applied by us to evaluate evidence for benefits, risks, and uncertainties pertaining to the breastmilk ecosystem. Here, we discuss the potential role of the evidence map as a risk analysis methodology to guide scientific and societal efforts to: (1) enhance ecosystem resilience, (2) ‘manage our microbes’, and (3) minimize the adverse effects of both acute and chronic diseases.